IDYA
Price
$21.10
Change
-$0.00 (-0.00%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
1.85B
67 days until earnings call
SNDX
Price
$11.16
Change
+$0.20 (+1.82%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
960.29M
66 days until earnings call
Interact to see
Advertisement

IDYA vs SNDX

Header iconIDYA vs SNDX Comparison
Open Charts IDYA vs SNDXBanner chart's image
IDEAYA Biosciences
Price$21.10
Change-$0.00 (-0.00%)
Volume$15.76K
Capitalization1.85B
Syndax Pharmaceuticals
Price$11.16
Change+$0.20 (+1.82%)
Volume$69.71K
Capitalization960.29M
IDYA vs SNDX Comparison Chart
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. SNDX commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Buy and SNDX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (IDYA: $21.08 vs. SNDX: $11.16)
Brand notoriety: IDYA and SNDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 45% vs. SNDX: 45%
Market capitalization -- IDYA: $1.85B vs. SNDX: $960.29M
IDYA [@Biotechnology] is valued at $1.85B. SNDX’s [@Biotechnology] market capitalization is $960.29M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whileSNDX’s FA Score has 1 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • SNDX’s FA Score: 1 green, 4 red.
According to our system of comparison, IDYA is a better buy in the long-term than SNDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 6 TA indicator(s) are bullish while SNDX’s TA Score has 6 bullish TA indicator(s).

  • IDYA’s TA Score: 6 bullish, 4 bearish.
  • SNDX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both IDYA and SNDX are a good buy in the short-term.

Price Growth

IDYA (@Biotechnology) experienced а +5.14% price change this week, while SNDX (@Biotechnology) price change was +5.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.85%. For the same industry, the average monthly price growth was +10.46%, and the average quarterly price growth was -0.86%.

Reported Earning Dates

IDYA is expected to report earnings on Aug 12, 2025.

SNDX is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+7.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($1.85B) has a higher market cap than SNDX($960M). SNDX YTD gains are higher at: -15.582 vs. IDYA (-17.977). SNDX has higher annual earnings (EBITDA): -318.27M vs. IDYA (-356.46M). IDYA has more cash in the bank: 693M vs. SNDX (516M). SNDX has less debt than IDYA: SNDX (1.84M) vs IDYA (26M). SNDX has higher revenues than IDYA: SNDX (43.7M) vs IDYA (7M).
IDYASNDXIDYA / SNDX
Capitalization1.85B960M192%
EBITDA-356.46M-318.27M112%
Gain YTD-17.977-15.582115%
P/E RatioN/AN/A-
Revenue7M43.7M16%
Total Cash693M516M134%
Total Debt26M1.84M1,415%
FUNDAMENTALS RATINGS
IDYA vs SNDX: Fundamental Ratings
IDYA
SNDX
OUTLOOK RATING
1..100
167
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
84
Overvalued
PROFIT vs RISK RATING
1..100
64100
SMR RATING
1..100
4595
PRICE GROWTH RATING
1..100
6090
P/E GROWTH RATING
1..100
1003
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (61) in the null industry is in the same range as SNDX (84) in the Biotechnology industry. This means that IDYA’s stock grew similarly to SNDX’s over the last 12 months.

IDYA's Profit vs Risk Rating (64) in the null industry is somewhat better than the same rating for SNDX (100) in the Biotechnology industry. This means that IDYA’s stock grew somewhat faster than SNDX’s over the last 12 months.

IDYA's SMR Rating (45) in the null industry is somewhat better than the same rating for SNDX (95) in the Biotechnology industry. This means that IDYA’s stock grew somewhat faster than SNDX’s over the last 12 months.

IDYA's Price Growth Rating (60) in the null industry is in the same range as SNDX (90) in the Biotechnology industry. This means that IDYA’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's P/E Growth Rating (3) in the Biotechnology industry is significantly better than the same rating for IDYA (100) in the null industry. This means that SNDX’s stock grew significantly faster than IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYASNDX
RSI
ODDS (%)
Bearish Trend 2 days ago
53%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
87%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 15 days ago
77%
Bearish Trend 22 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
68%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IFTAX12.45N/A
N/A
Voya International High Div Low Vol A
FOCPX20.81N/A
N/A
Fidelity OTC
MSTFX11.22N/A
N/A
Morningstar International Equity
FOBAX20.08-0.06
-0.30%
Tributary Balanced Instl
CGIOX47.08-0.19
-0.40%
Calamos Growth and Income R6